NCT02489318 2026-02-02TITANAragon Pharmaceuticals, Inc.Phase 3 Active not recruiting1,052 enrolled 13 charts 1 FDA
NCT01715285 2025-02-04A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)Janssen Research & Development, LLCPhase 3 Completed1,209 enrolled 16 charts 1 FDA